Pharmafile Logo
Pharmafocus logo
Advanced Search

breast cancer

Showing 15 posts of 177 posts found.

nhs_sign

NHS England seals access deals with big pharma for breast cancer and MS

November 9, 2017
Sales and Marketing Cancer, Mavenclad, Merck, NHS, NHS England, NICE, Perjeta, Roche, Simon Stevens, breast cancer, multiple sclerosis

NHS England has entered into a commercial agreement with Merck which aims to provide access to innovative treatments for both …

News
shutterstock_206748499

17,000 English patients are surviving Stage 4 cancer for two years or more, new data shows

November 8, 2017
Research and Development Cancer, bladder cancer, breast cancer, colon cancer, lung cancer, pharma, prostate cancer

At least 17,000 people in the UK are living with Stage 4 cancer and have survived for two years or …

News
novartis_outside_1

Novartis’ Kisqali smashes Phase 3 primary endpoint in breast cancer for second time

November 8, 2017
Research and Development Cancer, Kisqali, Novartis, breast cancer, pharma

Novartis has revealed that its immunotherapy drug Kisqali (ribociclib) met its primary endpoint of progression-free survival in its second Phase …

News
mit-ai-cancer-detection-01_0

Breakthrough AI able to identify 97% of breast cancer risk

October 18, 2017
Research and Development MIT, biotech, breast cancer, drugs, pharma, pharmaceutical

 Scientists at MIT’s Computer Science and Artificial Intelligence Laboratory have developed a machine learning AI system that is able diagnose …

News
rocherooflr

FDA awards Roche priority review in HER2-positive breast cancer

October 2, 2017
Sales and Marketing Cancer, FDA, Herceptin, Perjeta, Roche, breast cancer, pharma, pharmaceutical

Roche has revealed that its monoclonal antibody Perjeta (pertuzumab) has been awarded priority review by the FDA as an adjuvant …

News
astrazeneca_building_white

NICE rejects AstraZeneca’s breast cancer drug Faslodex

September 1, 2017
Medical Communications, Sales and Marketing AstraZeneca, Cancer, Faslodex, breast cancer, life sciences, pharma, pharmaceutical

NICE has announced its decision to not recommend AstraZeneca’s breast cancer drug Faslodex (fulvestrant) in women who have oestrogen-receptor-positive, locally …

News

Novartis gets EU nod for potential blockbuster breast cancer drug

August 24, 2017
Sales and Marketing CDK4/6, Novartis, biotech, breast cancer, drugs, pharma, pharmaceutical

Novartis has released that it has received marketing approval from the European Commission for its drug for the treatment of …

News
800px-cancer_cells_1

Chemotherapy can spread breast cancer to lungs, study finds

August 9, 2017
Research and Development Cancer, breast cancer, life sciences, lung cancer, pharma, pharmaceutical

Researchers at Ohio State University have discovered that, as well as forming a key part of treatment strategies to fight …

News
breast_cancer

Puma Biotech’s breast cancer drug gets FDA committee nod

May 25, 2017
Medical Communications, Sales and Marketing Puma Biotech, breast cancer, neratinib

Puma Biotechnology breast cancer drug that could be used to reduce the risk of disease recurrence has been boosted by …

News

Novartis secures first-line FDA approval in breast cancer indication

March 14, 2017
Manufacturing and Production, Sales and Marketing Kisqali, Novartis, breast cancer

The FDA has approved Kisqali (ribociclib) in combination with letrozole for the first-line treatment of postmenopausal women with hormone receptor …

News
breast_cancer

One in five women with breast cancer could benefit from existing therapy

March 14, 2017
Manufacturing and Production, Research and Development Wellcome Trust Sanger Institute, breast cancer, parp inhibitors

A new study emerging from the Wellcome Trust Sanger Institute has discovered that there are more cases of breast cancer …

News

NICE rejects Pfizer’s first-in-class breast cancer drug

February 3, 2017
Medical Communications, Sales and Marketing NICE, Pfizer, breast cancer

NICE has published draft guidelines which reject Pfizer’s Ibrance (palbociclib) based primarily on the cost of the drug but also …

News
eisai_halaven_eribulin_web

Eisai & Clinigen to bring breast cancer drug to South Africa

December 1, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Clinigen, Eisai, South Africa, breast cancer

Eisai and Clinigen have formed a collaboration to deliver the former’s cancer treatment Halaven (eribulin) to women in South Africa …

News

NICE recommends 4p breast cancer drug for healthy women

November 29, 2016
Research and Development, Sales and Marketing NICE, anastrozole, breast cancer

NICE has published new draft guidance calling for women with a strong family history of breast cancer to be offered …

News
images

NICE approves Roche’s Perjeta for breast cancer

November 16, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NICE, Perjeta, Roche, breast cancer

NICE has announced its approval of Roche’s Perjeta (pertuzumab) as a neoadjuvant treatment of HER2-positive, locally advanced, inflammatory or early-stage …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025